Background/aims: Since GH plays an important role in bone mineralization, and several studies demonstrated the positive influence of a higher calcium intake on bone mass, we studied the effect of calcium supplementation in GHD children during GH therapy. Methods: 28 prepubertal GHD children, 5.0–9.9 years old, were assigned to two groups: group A (n = 14; 7 females) treated with GH, and group B (n = 14; 7 females) treated with GH + calcium gluconolactate and carbonate (1 g calcium/day per os). Auxological parameters, total bone mineral content (TBMC) and density (TBMD), leg BMC and BMD, lumbar BMD, fat mass (FM) and lean tissue mass (LTM), blood 25-hydroxyvitamin D (25-OHD), parathyroid hormone (PTH), osteocalcin (OC) and urinary N-terminal telopeptide of type I collagen (NTx) were determined at the start of therapy and after 1 and 2 years of treatment. Results: During the 2 years of the study, TBMC, TBMD, leg BMC and BMD (but not lumbar BMD) increased in both groups of patients, however after 2 years of treatment they were significantly higher in the calcium-supplemented group B than in group A (p < 0.05, for all parameters). At the start of therapy, in both groups of patients percentage FM was higher and total and leg LTM lower than in controls (p < 0.05 for each parameter). Thereafter, FM decreased and LTM increased and after 2 years they were both different from baseline (p < 0.05). After 2 years of treatment, leg BMC and BMD were more positively correlated with regional leg LTM in patients of group B (r = 0.834 and r = 0.827, respectively; p < 0.001) than in patients of group A (r = 0.617 and r = 0.637, respectively; p < 0.05). 25-OHD and PTH levels were in the normal range in all patients at the start and during treatment. OC levels were lower and urinary NTx levels higher in patients than in controls (p < 0.05 for both parameters), either at the start and after 1 year of treatment. After 2 years of treatment, OC levels were significantly higher than at the start of the study (p < 0.05) in both groups of patients, but they were higher in group B than in group A (p < 0.05); on the contrary, urinary Ntx levels were lower in group B than in group A (p < 0.05). Conclusion: In GHD children, treated with GH, calcium supplementation improved bone mass; it may aid in reaching better peak bone mass and in protecting weight-bearing bones, usually completed in childhood to maximum levels, from risk of osteoporosis and fractures later in life.

Keywords:
Growth hormone-deficient children, Calcium supplementation, Bone mineral content, Bone mineral density, Dual-energy X-ray absorptiometry
1.
Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G: Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 1998;83:3150–3154.
2.
Van der Sluis IM, Boot AM, Hop WC, de Rijke YB, Krenning EP, de Muinck Keizer-Schrama SMPF: Long-term effects of growth hormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone-deficient children: a 6-year follow-up study. Horm Res 2002;58:207–214.
3.
Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hubner C, Shaw NJ, Dunger DB, Cheetman TD, Savage MO, Monson JP: The effect of cessation GH therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003;88:1658–1663.
4.
Baroncelli GI, Bertelloni S, Sodini F, Saggese G: Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol 2004;60:175–184.
5.
Bex M, Bouillon R: Growth hormone and bone health. Horm Res 2003;60(suppl 3):80–86.
6.
Rizzoli R, Bonjour JP: Determinants of peak bone mass and mechanisms of bone loss. Osteoporosis Int 1999;9(suppl 2):S17–S23.
7.
Stear SJ, Prentice A, Jones SC, Cole TJ: Effect of a calcium and exercise intervention on the bone mineral status of 16- to 18-year-old adolescent girls. Am J Clin Nutr 2003;77:985–992.
8.
Prentice A, Ginty F, Stear SJ, Jones SC, Laskey MA, Cole TJ: Calcium supplementation increases stature and bone mineral mass of 16- to 18-year-old boys. J Clin Endocrinol Metab 2005;90:3153–3161.
9.
Johnston CC Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock M: Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82–87.
10.
Bonjour JP, Carrie AL, Ferrari S, Clavien H, Slosman D, Theintz G, Rizzoli R: Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997;99:1287–1294.
11.
Matkovic V, Goel PK, Badenshop-Stevens NE, Landoll JD, Li B, Ilich JZ, Skugor M, Nagode LA, Mobley SL, Ha EJ, Hangartner TN, Clairmont A: Calcium supplementation and bone mineral density in females from childhood to young adulthood; a randomized controlled trial. Am J Clin Nutr 2005;81:175–188.
12.
Lee WTK, Leung SSF, Wang SH, Xu JC, Zeng WP, Lau J, Oppenheimer SJ, Cheng JC: Double-blind, controlled calcium supplementation and bone mineral accretion in children accustomed to a low calcium diet. Am J Clin Nutr 1994;60:744–750.
13.
Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, Tatò L: Prevention of bone mineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment. J Clin Endocrinol Metab 1999;84:1992–1996.
14.
Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, Tatò L: Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88:1096–1101.
15.
Angus RM, Sambrook PN, Pocok NA, Eisman JA: A simple method for assessing calcium intake in Caucasian women. J Am Diet Assoc 1989;89:209–214.
16.
Verschuur R, Kemper HCG: Habitual physical activity. Med Sport Sci 1985;20:55–65.
17.
Cacciari E, Milani S, Balsamo A, Dammaco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M: Italian cross-sectional growth charts for height, weight and BMI (6–10 years). Eur J Clin Nutr 2002;56:171–180.
18.
Greulich WW, Pyle SI: Radiologic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
19.
Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tatò L: Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr 2003;92:12–16.
20.
Kroger H, Vainio P, Nieminen J, Kotamieni A: Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. Bone 1995;17:157–159.
21.
Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY: Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005;26:114–146.
22.
Zamboni G, Antoniazzi F, Radetti G, Musumeci C, Tatò L: Effect of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency. J Pediatr 1991;119:483–485.
23.
Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G: Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993;122:37–45.
24.
Monson JP, Drake WM, Carroll PV, Weaver JU, Rodriguez-Arnao J, Savage MO: Influence of growth hormone on accretion of bone mass. Horm Res 2002;58(suppl 1):52–56.
25.
Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muinck Keizer-Schrama SMPF: Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 1997;82:57–62.
26.
Pietrobelli A, Faith MS, Wang J, Brambilla P, Chiumello G, Heymsfield SB: Association of lean tissue and fat mass with bone mineral content in children and adolescents. Obes Res 2002;10:56–60.
27.
White HD, Ahmad AM, Durham BH, Patwala A, Whittingham P, Fraser WD, Vora JP: Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients. J Clin Endocrinol Metab 2005;90:3371–3380.
28.
Branca F: Physical activity, diet and skeletal health. Public Health Nutr 1999;2:391–396.
29.
Boot AM: Body composition and bone mineral density in adolescents with partial growth hormone deficiency. J Clin Endocrinol Metab 2003;88:5099–5100.
30.
Mei Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH: Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. Am J Clin Nutr 2002;75:978–985.
31.
Hogler W, Briody JN, Woodhead HJ, Chan A, Cowell CT: Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 2003;143:81–88.
32.
Crabtree NJ, Kibirige MS, Fordham JN, Banks LM, Muntoni F, Chinn D, Boivin CM, Shaw NJ: The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004;35:965–972.
33.
Frost HM, Schonau E: The ‘muscle-bone unit’ in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000;13:571–590.
34.
Wren TAL, Liu X, Pitukcheewanont P, Gilsanz V and members of the Bone Mineral Density in Childhood Study: Bone acquisition in healthy children and adolescents: comparisons on dual-energy x-ray absorptiometry and computed tomography measures. J Clin Endocrinol Metab 2005;90:1925–1928.
35.
Arabi A, Tamin H, Nabulsi M, Maalouf J, Khalifé H, Choucair M, Vieth R, El-Hajj Fuleihan G: Sex difference in the effect of body-composition variables on bone mass in healthy children and adolescents. Am J Clin Nutr 2004;80:1428–1435.
36.
Chevalley T, Bonjour JP, Ferrari S, Hans D, Rizzoli R: Skeletal site selectivity in the effects of calcium supplementation on areal bone mineral density gain: a randomized, double-blind, placebo-controlled trial in prepubertal boys. J Clin Endocrinol Metab 2005;90:3342–3349.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.